FDA puts Hemopure trial on hold as it reviews safety

The FDA has put a clinical trial for Biopure's Hemopure therapy on hold saying it needs answers to several safety questions. The Navy has joined with Biopure to seek approval for a trial of the cow-blood derivative on trauma patients outside of hospitals. Researchers want to test Hemopure in a mid- to late-stage trial that would test the safety and effectiveness of the therapy on patients suffering acute blood loss. The blood derivative is designed to be stored at room temperature and remain viable for years.

- read this AP report for more

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.